Review

Activatable NIR-II organic fluorescent probes for bioimaging

Xiaoning Zhang¹*, Shasha Li¹*, Huizhen Ma², Hao Wang¹**, Ruiping Zhang³**, Xiao-Dong Zhang¹,²**

¹. Tianjin Key Laboratory of Brain Science and Neural Engineering, Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin 300072, China.
². Department of Physics and Tianjin Key Laboratory of Low Dimensional Materials Physics and Preparing Technology, School of Sciences, Tianjin University, Tianjin 300350, China.
³. The Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Taiyuan, 030000, China.

*Equal contributions to this work.
**Corresponding authors: Xiaodong Zhang, Email: xiaodongzhang@tju.edu.cn; Ruiping Zhang, Email: zrp_7142@sxmu.edu.cn; Hao Wang, Email: hao_wang@tju.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2022.01.24; Accepted: 2022.04.01; Published: 2022.04.11

Abstract

NIR-II imaging is developed rapidly for noninvasive deep tissue inspection with high spatio-temporal resolution, taking advantage of diminished autofluorescence and light attenuation. Activatable NIR-II fluorescence probes are widely developed to report pathological changes with accurate targeting, among which organic fluorescent probes achieve significant progress. Furthermore, the activatable NIR-II fluorescent probes exhibited appealing characteristics like tunable physicochemical and optical properties, easy processability, and excellent biocompatibility. In the present review, we highlight the advances of activatable NIR-II fluorescence probes in design, synthesis and applications for imaging pathological changes like reactive oxygen species (ROS), reactive nitrogen species (RNS), reactive sulfur species (RSS), pH, hypoxia, viscosity as well as abnormally expressed enzymes. This non-invasive optical imaging modality shows a promising prospect in targeting the pathological site and is envisioned for potential clinical translation.

Key words: NIR-II fluorescence, organic fluorescent probes, responsive probes, pathological changes, bioimaging

Introduction

Fluorescence imaging in the second near-infrared window (NIR-II, 1000-1700 nm) is developed rapidly for noninvasive deep tissue investigation with high spatio-temporal resolution due to diminished autofluorescence light attenuation [1-8]. For optical in vivo bioimaging, the penetration depth of photons is mainly influenced by the absorption and scattering of tissue components. Meanwhile, the autofluorescence from the tissue will produce background noise. Compared with the traditional near-infrared window (NIR-I, 750-900 nm), the NIR-II fluorescence has reduced photon scattering and diminished autofluorescence taking advantage of its long wavelength, which allows the photon to penetrate deeper biological tissue and improves the spatial resolution. Therefore, a variety of NIR-II fluorescence probes are exploited for biosensing and bioimaging [9-21]. Thus far, a wide variety of materials especially inorganic nanostructures have been applied in fluorescence imaging [22-24], such as carbon nanotubes [24-26], quantum dots (QDs) [27-29], and lanthanide-doped nanoparticles (LnNPs) [30, 31], which may arise safety concern about cumulative toxicity. Organic fluorescent probes offer a better alternative due to their tunable physical and optical properties controlled by structural engineering, easy processability, and excellent biocompatibility [32-39].

NIR-II fluorescence probes show potential in cancer imaging and diagnosis [40], medical detection [8], and vascular bioimaging [41]. It is worth noting that, repurposing NIR-I probes with emission in the NIR-II window, especially the ones approved
clinically, provides an important development strategy for NIR-II fluorescence proves to accelerate the clinical translation [42]. Organic small molecules and polymers are the main forms of organic fluorescent probes. Organic small molecules are mostly designed based on the D-A-D architectures, cyanine, and boron dipyrromethene (BODIPY) scaffold, and derived multiple imaging agents and functional fluorescent probes with high biocompatibility, fast excretion, and superior optical properties. However, low quantum yield (QY), short emission wavelength, and time-consuming synthesis and purification process, still limit their further bioimaging application. Polymers are mostly designed based on a-electron delocalized backbones, and attract attentions to develop fluorescent probes with superior optical properties and adjustable structure. However, improving the biocompatibility and accelerating the excretion are still challenges. To date, researchers have made great progress on the development of organic fluorescent probes, and organic fluorescence probes showed promising prospects on bioimaging.

Most of the fluorescence probes are “always-on” probes, which improve the target-to-background ratio (TBR) by accumulation and retention in the target tissues. However, it may produce more false-positive signals with no specificity and reduce the imaging effect. While activatable probes produce strong signals only under the specific biological alterations compared with the “always-on” probes. These alterations are usually associated with pathological changes in the target site such as abnormal redox, pH, enzyme expression, etc., which makes the activatable probes more accurate for specific disease diagnoses [43-46].

Multiple “turn-on” fluorescence probes including nanostructures in NIR-I and NIR-II windows were reported and reviewed [47, 48], and in the present review, we highlight the up-to-date advances of activatable organic NIR-II fluorescence probes in design, synthesis and application for the detection of ROS, RNS, RSS, pH, viscosity and enzyme. This state-of-the-art, non-invasive and highly specific optical imaging modality shows promising prospects in understanding the fundamental pathophysiology of diseases and is envisioned for potential clinical translation.

**Redox species-activatable probes**

Redox homeostasis plays a critical role in maintaining cellular function related to necessary physiological activities, and redox imbalance is related to the occurrence and development of multiple diseases such as cancer [49, 50]. Important redox species in the living organism include ROS, RNS, and RSS. ROS and RNS can be generated through exogenous and endogenous sources. Exogenous sources may include UV radiations, γ-radiations, drugs, food, toxic chemicals, etc. The endogenous sources may include direct producing enzymes, indirect producing enzymes, neutrophils, cytokines and other components of white blood cells, mitochondrial, metals and side effects of various diseases. These molecules interact with each other to engage in important physiological activities, and multiple clinical disorders are associated with the early initiation of these important signaling molecules. RSS plays the function of regulating protein catalytic activity through polysulfidation, the formation of polysulfides [S-(S)n-H] on their reactive cysteine residues. Both ROS and RNS can lead to cellular dysfunction via lipid peroxidation, protein and DNA damage when present in high concentrations. Therefore, monitoring the ROS, RNS, and RSS provides a powerful tool for related disease diagnoses such as Parkinson’s disease and Alzheimer’s disease [51-54].

In the past decades, many redox-responsive fluorescent probes have been developed [55-57], among which organic fluorescent probes have been widely investigated owing to good biocompatibility and easily tunable structure and optical properties (Figure 1, Table 1 and Figure 2-8). Probes are designed based on the reactivities of the redox species and fluorescence mechanisms such as photon-induced electron transfer (PET), intramolecular charge transfer (ICT), excited-state intra molecular proton transfer (ESIPT), and fluorescence resonance energy transfer (FRET). For instance, to detect ROS, reductive groups like lactam and double bond were adopted to react with the analyte and make the probes emit fluorescence. o-Phenylenediamine is commonly used to form triazole with nitric oxide for inhibiting PET of the probe and making it fluorescent.

**ROS-activatable probes**

ROS are produced in necessary physiological processes. ROS with high reactivity consists of singlet oxygen (1O2), superoxide anion (O2•−), hydrogen peroxide (H2O2), hydroxyl radical (•OH), hypochlorous acid/hypochlorite (HOCl/-OCl), hypobromous acid/hypobromite (HOB Br/-OBr) and peroxy radical (ROO•) [52, 54, 58]. While excess ROS can induce oxidative stress and damage tissues and cells, demonstrating a crucial pathogenic mechanism...
in conditions such as inflammatory diseases, cancers, and neurodegenerative disorders. Recently, a variety of probes have been developed for the detection of ROS, providing tools for early disease detection. Additionally, the structure-activity relationship between fluorescence probes structure and ROS have been revealed and can be used to guide the design of new probes.

Table 1. Representative organic responsive NIR-II fluorescence probes

| Probes | Structure | Analyte | Photochemical designed Mechanism | Absorb- ance [nm] | ex [nm] | em [nm] | Imaging applications | Detection limit | Biocompatibility | t1/2 | SNR | QY | Ref |
|--------|-----------|---------|----------------------------------|------------------|--------|--------|-----------------------|----------------|-----------------|------|-----|---|-----|
| Hydro- 1080 | -OH | Target-induced change in the chemical structures of fluorescent probes | 1021 | 1004 | 1044 | Monitor - OH induced by LPS and APAP overdose | 0.5 nM | The results of the MTT assay toward HeLa cells show low cytotoxicity of Hydro-1080 (0–20 µM) | 6.0 | 0.45% | [73] |
| SPNP25 | CIO- | Bio-erasable intermolecular donor-acceptor interaction | 700 | 808 | 1000-1700 | in vivo dynamic inflammation sensing | 0.68 µM | The results of in vivo toxicity show no obvious long toxicity in the mice treated with SPNP25 (50 µg) | ~2.5 | 17.5 | 0.21% | [72] |
| HP- H2O2 | H2O2 | Photoinduced electron-transfer | 826 | 808 | 937 | ALI and AKI imaging | 55.9 nM | The results of histology show no liver-toxicity in the mice treated with HP- H2O2 (50 µM) | 5 | 0.10% | [83] |
| IRBTP-B | ONOO- | Target-induced change in the chemical structures of fluorescent probes | 600 | 808 | 1100 | APAP-induced hepatotoxicity monitoring | 17.5 | The results of histology show no liver toxicity in the mice treated with IRBTP-B (1 mM) | 17.4 | 0.091±0.014 | [84] |
| PN1100 | ONOO- | FRET | 1089 | 808 | F0/F150 | APAP-induced hepatotoxicity monitoring | 0.35 µM | The results of MTT assay show low cytotoxicity of AOSNP (200 µg/mL) | 0.35% | [85] |
| AOSNP | NO | Transforming weak acceptors of fluorescent probes into strong acceptors to shift the fluorescence | 680 | 808 | 1000-1700 | APAP-induced hepatotoxicity monitoring | 37 nM | The identification of colon cancer cells and differentiation between types of living cells | 5.7 | 0.37% | [86] |
| NIR-II8Si | H2S | Target-induced change in the chemical structures of fluorescent probes | 520 | 780 | 900 | The identification of colon cancer cells and differentiation between types of living cells | 106 nM | The results of histopathology and blood biochemistry show low toxicity in the mice treated with Nano-PT (100 nmol × SS) | ~6.5 | 8.3±0.0034% | [93] |
| Nano-PT | H2S | Target-induced change in the chemical structures of chromophores | 540, 790 | 785 | Photothermal therapy of CRC | 51 nM | The results of histopathology and blood biochemistry show low toxicity in the mice treated with Nano-PT (100 nmol × SS) | 10.64 | 0.17% | [94] |
| WH-3 | H2S | ICT | 575, 925 | 925 | 1140 | Real-time Monitoring of endogenous H2S generation and fluctuation in tumor-bearing mice | 85 nM | The results of in vivo toxicity showed that WH-3 has superior biocompatibility and biosafety (100 µL, 1.0 mM) | 7.5 | [95] |
| Probes        | Structure | Analyte | Photochemical designed Mechanism | Absorbance | ex | em | Imaging applications | Detection limit | Biocompatibility | t1/2 | SNR | QV | Ref  |
|--------------|-----------|---------|-----------------------------------|------------|----|----|----------------------|----------------|------------------|------|-----|----|------|
| BTC1070      | ![BTC1070](image1) | pH      | ICT                              | 1015        | 808 |     | Noninvasive ratiometric quantification of gastric pH | 1-4            | The results of the cytotoxicity assay show high cell viability of BTCs (40 μM) | 9.42 | 0.016% | [110] |
| NIRII-RT-NO  | ![NIRII-RT-NO](image2) | pH      | Target-induced change in the chemical structures of fluorescent probes | 856         | 925 |     | Real-time monitoring of drug-induced hepatotoxicity | The results of the MTT assay toward HeLa cells show low cytotoxicity of NIRII-RTs (0-10 μM) | 1.42% | [111] |
| pTAS         | ![pTAS](image3) | pH      | FRET                             | 895         | 908 | 1026 | In vivo dynamic tumor pH monitoring | 6.11-7.22 | 2.08% | [100] |
| IR1048-MZ    | ![IR1048-MZ](image4) | Hypoxia | Target-induced change in the chemical structures of fluorescent probes | 980         | 980 | 1046 | Hypoxia-activated photothermal therapy | The results of in vivo toxicology show high biocompatibility of IR1048-MZ (40 μg/mL) | 30 | 0.006% | [115] |
| NTR-InD      | ![NTR-InD](image5) | NTR     | Target-induced change in the chemical structures of chromophores | 553         | 750 | 1000-1300 | Monitoring of enzyme activities for Targeted cancer cell imaging and differentiation | The probes show low cytotoxicity toward living cells | 10.6 | 3.9% | [129] |
| RHC-NO2      | ![RHC-NO2](image6) | NTR     | Target-induced change in the chemical structures of fluorescent probes | 677         | 808 | 921  | NIR-II tumor imaging | The results of the MTT assay toward A549 and HeLa cells show low cytotoxicity of RHC-NO2 (0–100 μM) | <0.01 | [130] |
| BOD-II-NAG-NP| ![BOD-II-NAG-NP](image7) | NAG     | The hydrolyzation of N-acetyl-p-D-glucosamine residues | 490         | 710 | 1000 | Tracking the activity of NAG in vivo and exploring its potential role in AKI or CKD diagnosis | The results of the cytotoxicity assay show low cytotoxicity of BOD-II-NAG-NP (0–40 μM) | 15 | 0.002% | [133] |
| WD-NO2       | ![WD-NO2](image8) | Viscosity | Target-induced change in dihedral angle and conjugated region | 768         | 818 | 982  | Track the variation of viscosity in diabetes-induced liver injury | The results of the MTT assay toward HeLa cells show very low cytotoxicity of WD-NO2 (0–30 μM) | 4.4  | 0.23% | [121] |
| HISSNPs      | ![HISSNPs](image9) | Hyaluronidase and thiols | Target-induced change in aggregation state | 810         | 1050 | 1000-1700 | Ultra-high specific imaging of tumor in vivo | The results of in vivo toxicology show low toxicity in the mice treated with HISSNPs (35 mg/µg) | 15.4 | [142] |
| BOD-NH-SC    | ![BOD-NH-SC](image10) | NO and H2S | Aromatic nucleophilic substitution | 664         | 808 | 936  | Monitoring the alternating existence of NO and H2S in living cells | The results of the MTT assay show low cytotoxicity of BOD-NH-SC (0.1 μM) | 0.06% | [143] |
| PN910        | ![PN910](image11) | ROS/RNS and base | ICT | 675         | 808 | 910  | Monitoring cystitis and colitis | The results of in vivo toxicology show little toxicity in the mice treated with Chrodol-3 (10 mg/kg) | 10  | [146] |

The red part on each fluorophore represents the reaction moiety that can be activated by the analytes and enable the molecular luminescence.
As one of the most common ROS, \( \text{H}_2\text{O}_2 \) is involved in various inflammatory diseases and it can serve as an oxidative stress biomarker. The sensing strategies of \( \text{H}_2\text{O}_2 \)-activatable probes include the reaction of aryl boronates or phenylboronic acid to phenols (probe 1, 2), oxidation of phenol to quinone (probe 3), the conversion of oxonium or diketone to acid (probe 4), and the cleavage of carbon-carbon double bond (probe 5) [59-63]. In the presence of \( \text{H}_2\text{O}_2 \) the probes turn into corresponding reaction products, causing changes in fluorescence properties.

\( \text{HOCl} \) plays a significant role in the immune system \emph{in vivo}. Endogenous \( \text{HOCl} \) is mainly generated from \( \text{H}_2\text{O}_2 \) and chloride ions (\( \text{Cl}^- \)) catalyzed by the heme enzyme myeloperoxidase (MPO) in the neutrophils and exist as a mixture of the undissociated acid and the hypochlorite ion at physiologic pH levels. The over-production of \( \text{HClO} / \text{ClO}^- \) can be the biomarker of some ROS-related diseases. Based on the strong oxidation ability of \( \text{HClO} / \text{ClO}^- \), the sensing strategy of \( \text{HClO} / \text{ClO}^- \)-activatable probes is to adopt oxidizable building blocks like double bonds (probe 6), lactam or lactone (probe 7), thioether or selenide (probe 8) and so on [64-66].

\( \cdot \text{OH} \) is widely associated with various pathological processes, and the detection of \( \cdot \text{OH} \) \emph{in situ} and \emph{in vivo} is vital to understand these mechanisms. Based on the strong oxidation ability of \( \cdot \text{OH} \), the sensing strategies of \( \cdot \text{OH} \)-activatable probes are designed on the oxidation of phenothiazines (probe 9) and the pyrrolidine (probe 10) [67, 68]. Other ROS like \( \text{O}_2^- \), \( \text{HOBr}^- / \text{OBr}^- \) have similar sensing strategies based on their specific natures (probe 11, 12, 13) [69-71].

In 2018, a \( \text{ClO}^- \)-activatable NIR-II fluorescence probe SPNP25 was developed by blending a \( \text{ClO}^- \)-sensitive organic semiconducting non-fullerene acceptor (ITTC) with a \( \text{ClO}^- \)-inert semiconducting polymer donor (PDF) in an amphiphilic-polymer-coated single nanoparticle (Figure 2A-C). This is based on a fairly generic bio-erasable intermolecular donor-acceptor interaction strategy. The specific response to \( \text{ClO}^- \) is achieved by degradation of ITTC in the presence of \( \text{ClO}^- \), thus erasing the intermolecular donor-acceptor interaction and uncaging NIR-II fluorescence of PDF. The \emph{in vivo} NIR-II fluorescence imaging of \( \text{ClO}^- \) in an inflamed mouse model further confirms the specific response to \( \text{ClO}^- \) of SPNP25 (Figure 2D-E) [72]. This smart design strategy changes the fluorescence intensity utilizing the oxidative cleavage reaction by \( \text{ClO}^- \). While the probe still needs to be modified like reducing the size of SPNP25 to improve biocompatibility and improving QY for further clinical translation.

In 2019, an \( \cdot \text{OH} \)-activatable NIR-II fluorescence probe Hydro-1080 was designed based on direct breaking/recovering the conjugated system and rigid planar structure, which was successfully applied to imaging overproduced \( \cdot \text{OH} \) of hepatotoxicity (Figure 3A). In the presence of \( \cdot \text{OH} \), Hydro-1080 turns on its NIR-II emission at 1044 nm due to the recovered conjugated system. Hydro-1080 shows a perfect linear relationship with the concentration of \( \cdot \text{OH} \), which provides a tool for related diseases imaging (Figure 3B-C). The results show the successful imaging of overproduced \( \cdot \text{OH} \) on the liver injury model induced by lipopolysaccharide (LPS) and acetaminophen (APAP) compared with the control group. Furthermore, Hydro-1080 holds the application potential in the NIR-IIa imaging, with high signal-to-background ratios up to 6.0 (Figure 3D-E) [73]. This reduction synthesis route provides more bright ideas for the development of activatable NIR-II fluorescence probes. Hydrophobicity and QY of Hydro-1080 are the challenges of further application.

In 2021, an \( \text{H}_2\text{O}_2 \)-activatable NIR-II fluorescence probe HP-\( \text{H}_2\text{O}_2 \) was designed based on the stable heptamethine-cyanine HP-N dyes, introducing phenylboronic acid as an \( \text{H}_2\text{O}_2 \)-responsive element and fluorescence quencher (Figure 4A). HP-\( \text{H}_2\text{O}_2 \) shows increasing fluorescence intensity in the presence of \( \text{H}_2\text{O}_2 \) with increased concentration (Figure 4B). In the presence of \( \text{H}_2\text{O}_2 \), HP-\( \text{H}_2\text{O}_2 \) amplifies its NIR-II fluorescence intensity due to fast photoinduced electron transfer from cleavage of phenylboronic acid. Meanwhile, HP-\( \text{H}_2\text{O}_2 \) shows a perfect linear relationship with the concentration of \( \text{H}_2\text{O}_2 \) which provides a tool for inflammatory diseases imaging. Real-time imaging of healthy mice and acute lung injury/acute kidney injury with HP-\( \text{H}_2\text{O}_2 \) shows distinctly different fluorescence intensity (Figure 4C-F) [74], demonstrating the potential clinical utility. The work provides a convenient strategy to develop probes for various analytes and biomarkers via simple alkylation, acylation, or carbamylation of the N-methylamino attachment points. The balance between structure regulation and biocompatibility is a challenge for further application of these probes.

\begin{itemize}
 \item \textbf{RNS-activatable probes}:
 \end{itemize}

RNS mainly include nitrogen dioxide (\( \text{NO}_2 \)), peroxynitrite (\( \text{ONOO}^- \)), S-nitrosothiols (RSNO), nitric oxide (\( \text{NO} \)), and nitroxyl (\( \text{HNO} \)). RNS has a similar function to ROS in the organism [56, 75]. The mechanisms related to the key RNS species have been employed to develop RNS-activatable probes.

\( \text{ONOO}^- \) is formed from nitric oxide and superoxide without enzymatic catalysis and can oxidize various biomolecules such as thiols, lipids,
proteins, carbohydrates, DNA, and low-molecule weight anti-oxidants. Overproduction of ONOO⁻ would induce oxidative injury linked with a large number of diseases [75, 76]. The sensing strategies of ONOO⁻-activatable probes include the production of amido from dearylation reaction (probe 14), deboronation (probe 15), oxidation of unsaturated bond (probe 16), and decomposition of α-ketoamide group (probe 17) and so on [77-80]. NO can serve as an oxidative stress biomarker for diseases involving oxidative injury. The sensing strategies of NO-activatable probes are mostly based on the PET mechanism, including the generation of triazole the reaction from o-phenylenediamine (probe 18) and N-nitrosation reaction of aromatic secondary amine (probe 19) [81, 82].

Figure 1. The representative activatable NIR-II organic fluorescent probes. Detecting ROS (probes 1-13), RNS (probes 14-19), RSS (probes 20-24), pH (probes 25-29), viscosity (probes 30-32), enzymes (probes 33-36).
Figure 2. Activatable NIR-II probes for ClO⁻. (A) The structure and detection mechanism of SPNP25 for ClO⁻ by blending the hydrophobic donor PDF and acceptor ITTC. (B) Fluorescence spectra of the nanoprobe SPNP25 treated with ClO⁻ (0-40 µM). (C) Plots of the linear relationship between fluorescence intensity and concentrations of ClO⁻. (D) Real-time NIR-II fluorescence images of SPNP25 in LPS-pretreated and LPS/NAC-treated mice (Excitation: 808 nm laser, 40 mW cm⁻²). (E) Corresponding fluorescence intensity of the region of interest after administration of SPNP25. (F) The NIR-II fluorescence intensity enhancement of the ratio in different regions of interest. Figures adapted with permission from [72]. Copyright © 2018, John Wiley and Sons.

In 2019, an ONOO⁻-activatable NIR-II molecular probe IRBTP-B was developed based on the incorporation of the phenyl borate group and a NIR-II fluorescence turn-on benzothiopyrylium cyanines skeleton (Figure 5A). Initially, the conjugated π-electron system is divided in half due to the masking of phenyl borate. In the presence of ONOO⁻, the phenyl borate group was removed to turn on the NIR-II fluorescence with a good linear response to ONOO⁻ (Figure 5B-C). IRBTP-B was used to monitor the upregulation of ONOO⁻ and the remediation with N-acetyl cysteine (NAC) with a preclinical drug-induced liver injury model in vivo (Figure 5D-E) [83]. This work provides a strategy to design a variety of activatable NIR-II probes by masking the hydroxyl functionalized reactive site with an analyte-specific triggering group. Extending the emission to a longer wavelength (>1300 nm) may accelerate the clinical translation of the probe for drug-induced organism injury.

The same group reported an OONO⁻-activatable NIR-II probe PN1100 based on a panel of fluorescent dyes (CX) with chemotherapeutic and photostability (Figure 5F-G). PN1100 was designed by loading CX-1 and CX-3 into a micelle for OONO⁻ detection based on a FRET mechanism between CX-1 and CX-3 dyes (Figure 5H). Upon treatment with OONO⁻ (0-24 µM), the ratio of F920/F1130, attributed to the CX-1 and CX-3, increased exponentially due to the oxidation of CX-3 (Figure 5I-J). The in vivo detection of drug-induced hepatotoxicity with PN1100 was conducted by using APAP-treated mice as a model. The ratios of the APAP-treated group were higher than those of the PBS-treated and remediation (APAP+NAC) groups, which confirms the generation of OONO⁻ in the liver of APAP-treated mice (Figure 5K) [84]. CX dyes show great application potential in bioimaging due to their promising spectral properties and ease of synthesis. However, the development of analogs with a larger Stokes shift and further FRET-based applications are the challenges for future work.
In 2019, a NO-activatable organic semiconducting nanoprobe was fabricated, which was designed by FTBD and a polymer (styrene-co-maleic anhydride) (PSMA) with good water solubility by amidation (Figure 6A). The AOSNP turns on its second near-infrared window fluorescence by using a NO-sensitive organic semiconducting group (FTBD) for its primary sensing component. When being exposed to NO, FTBD can transform its energy acceptor units (benzo[c][1,2,5]thiadiazole-5,6-diamine) into stronger acceptors (benzotriazole derivatives) to redshift the fluorescence (Figure 6B). Furthermore, the fluorescence intensity ratio $F/F_0$ (where $F_0$ indicates the fluorescence intensity of the AOSNP without NO and $F$ is the fluorescence intensity in the presence of the indicated concentration of NO) showed a good linear relationship ($R^2 = 0.9961$) with NO concentration within various NO concentrations (0-35 µM) (Figure 6C). Based on its excellent response, the AOSNP has been successfully used for in vivo, in situ, real-time, and non-invasive NIR-II fluorescence monitoring of drug dose-dependent NO activity associated with hepatotoxicity, specifically for the commonly used anti-pain/fever drug APAP (Figure 6D) [85]. This work shows the potential of the NO-activatable probe in the detection of hepatotoxicity. However, designing probes with a longer emission wavelength and higher biocompatibility based on the strategy is a challenge for clinical application.

**RSS-activatable probes**

RSS is active as antioxidants and signaling agents in a variety of tissue types, including the liver, gastrointestinal system pancreas, brain, and circulatory system, which contribute to many physiological responses to maintain cellular health [56, 86]. RSS contain thiols (GSH, Cys, Hcy), disulfide (RSSR), persulfides (R-SH/H₂S₂), H₂S, sulfenic acid (RSOH), thyl radical (RS·), polysulfides (R₂Sn/H₂Sn, $n > 2$), and sulfur dioxide/sulfite/bisulfite (SO₂/ SO₃²⁻/HSO₃⁻) [56, 87]. Abnormal levels of RSS may contribute to many diseases such as Down syndrome, Alzheimer’s disease, cirrhosis, diabetes, and cancer-based on previous reports [62, 63]. The mechanisms related to some key RSS have been explored for the development of RSS-activatable probes.

---

**Figure 3. Activatable NIR-II probes for •OH.** (A) The structure and detection mechanism of Hydro-1080 for •OH. (B) NIR-II fluorescence spectra of Hydro-1080 treated with •OH (0.01-1.6 µM) under 980 nm excitation. (C) Plots of the linear relationship between fluorescence intensity at 1044 nm and concentrations of •OH in the range of 10-200 and 200-1000 nM. (D) NIR-II fluorescence images of mice injected with saline and LPS and intravenously injected with Hydro-1080 after 24 h. (E) NIR-II and NIR-Ila fluorescence images of mice injected with 0, 300, 500, 500 mg/kg APAP, respectively, and then intravenously injected with Hydro-1080. The last group is pretreated with inhibitor ABT. Figures adapted with permission from [73]. Copyright © 2019 American Chemical Society.
The production and metabolism of H$_2$S in mammalian cells are regulated by enzymes that are distributed throughout virtually every tissue type. Monitoring the dynamics of H$_2$S in vivo provides a better understanding of basic physiological and pathological mechanisms. Based on the nucleophilic and reducing capacity of H$_2$S, the sensing strategies include nucleophilic addition reaction (probe 20), H$_2$S-induced thiolysis (probe 21), the reduction of azide group (probe 22), etc. [88-90]. As a vital biomarker, GSH plays a key role in maintaining physiological homeostasis. Based on the nucleophilic capacity of GSH, the sensing strategies of the GSH-activatable NIR-II probes are mainly based on nucleophilic substitution or Michael addition reaction (probe 23, 24) [91, 92]. In general, the activatable probes are designed based on the nucleophilicity of the RSS.

The ratiometric NIR-II H$_2$S-responsive nano-probes NIR-II@Si were devised, which are comprised of an H$_2$S-responsive BODIPY (ZX-NIR) dye and an H$_2$S-inert aza-BODIPY (aza-BOD) dye for the internal reference (Figure 7A). Upon the H$_2$S stimuli, the NIR-II fluorescence of ZX-NIR at 900-1300 nm was lighted up due to the transformation of ZX-NIR into NIR-II-HS through aromatic nucleophilic substitution. Meanwhile, aza-BOD has poor overlapping with ZX-NIR and NIRII-HS and chemical inertness to H$_2$S, providing an ideal inference (Figure 7B). This target-specific activatable probe was used for...
visualization of colorectal cancers (CRC) in vivo in HCT116 subcutaneous xenograft nude mice (Figure 7C) [86]. The ratiometric probe provides a novel idea for the development of smart NIR-II activatable probes. Improving the loading percentage of responsive agents in the nanocomposites and improving biocompatibility are the challenges for further application. Subsequently, the same group developed an H₂S-activatable nanostructured photothermal agent (Nano-PT) for site-specific NIR-II fluorescence-guided photothermal therapy of CRC (Figure 7D). The Nano-PT not only emits NIR-II fluorescence in the presence of H₂S (Figure 7E) but also generates high NIR absorption, resulting in efficient photothermal conversion under NIR laser irradiation. The in vivo treatment outcome of the photothermal therapy with Nano-PT shows good tumor inhibition (Figure 7F) [93]. This work shows the potential of NIR-II responsive probes for photothermal therapy. Improving the biocompatibility of self-assemble nanoparticles can accelerate further application.

Figure 5. Activatable NIR-II probes for ONOO−. (A) The structure and mechanism of IRBTP-B. (B) Fluorescence spectra of IRBTP-B (10 µM) treated with ONOO− (0-11 µM). (C) Plots of the linear relationship between fluorescence intensity at 950 nm and concentrations of ONOO−. (D) Real-time NIR-II fluorescence imaging of livers of mice from IRBTP-B treated with PBS, APAP, and NAC + APAP respectively. (E) Relative fluorescence intensity of livers of mice treated with various substances followed by IRBTP-B over time. (F) The synthesis of CX dyes. (G) Corresponding absorption (solid) and emission (dot) spectra of CX dyes. (H) The structure and mechanism of IRBTP-O, which is constructed by loading CX-1 and CX-3 into a micelle. (I) Fluorescence spectra of PN1100 in the presence of ONOO−. (J) The ratio of F920/F1130 (fluorescence intensity at 920 nm and 1130 nm, respectively) of PN1100 upon addition with ONOO− (0-24 µM). (K) The ratio of F950/F1100 of the livers of mice treated with PBS, APAP, and NAC + APAP respectively, followed by PN1100 over time. Figures adapted with permission from [83, 84]. Copyright © 2019, American Chemical Society, and Copyright © 2019, John Wiley and Sons.
The NIR-II H$_2$S-responsive probes WH-X with the D-π-A structure were fabricated by introducing 4-Nitrothiophenol into the difluoro BODIPY fluorescent probe as the fluorescence quencher and specific recognition site. WH-3 was selected as the probe for H$_2$S imaging due to the balance of long emission (1020-1400 nm, centered at 1140 nm) and acceptable QY (0.17% in PBS) (Figure 7G). NIR-II fluorescence intensity centered at 1140 nm enhanced when WH-3 was treated with an increasing concentration of NaHS (Figure 7H), which can be attributed to the enhanced intramolecular charge-transfer process. Imaging results of mice show the fluorescence intensity of tumor sites increased along with tumor size amplification associated with increased H$_2$S levels (Figure 7I) [94]. WH-3 was successfully applied to real-time monitoring of endogenous H$_2$S generation and fluctuation in tumor-bearing mice. Improving the QY of activatable probes based on this flexible strategy is the key to the further application.

The NIR-II GSH-responsive probes LET-7 was composed of an anionic polymethylcyanide dye linked with a quenching group, 3,5-bis(trifluoromethyl)benzenethiol (BTBT). In the presence of GSH, LET-7 was transformed into turn-on signal reporter LET-G due to the replacement of the BTBT with GSH (Figure 8A). LET-7 showed the specific response to GSH and exhibited a perfect linear relationship with the concentration of GSH, which provides a tool for related diseases imaging (Figure 8B-C). A 4T1 tumor-bearing mouse model was established for the in vivo NIR-II FL monitoring of GSH. The result showed that the brightness and SBR of tumor regions are higher than those in normal tissue regions, which showed the application potential of LET-7 (Figure 8D-E) [95]. This novel design strategy can provide ideas for the detection of other disease-related biomarkers. However, extending the NIR-II emission to a longer wavelength and developing more stable probes based on the polymethylcyanide structure are the challenges for further applications.

**Microenvironment**

Tissue microenvironment factors such as pH, viscosity and oxygen pressure play a key role in maintaining the metabolism and normal physiological function. On the condition that the microenvironment varies, it can alter the metabolism and even remodel the tissue leading to pathological changes and proceeding to disease. For another, pathological changes also can result in microenvironment factors alteration. Therefore, the inspection of microenvironment factors can not only be a method for
early diagnosis but also provide clues for pathogenesis [96-98], and a variety of responsive organic NIR-II fluorescence probes were developed recently (Table 1 and Figure 9-12).

**pH-activatable probes**

The normal intracellular pH (pHi) level of adult cells is ~7.2 and extracellular pH (pHe) is ~7.4. pHi plays a critical role in normal physical activity such as ion transport, multidrug resistance (MDR) and proliferation, apoptosis. Abnormal pH values are usually associated with cellular dysfunction, leading to cancers or neurodegenerative disorders. For example, cancer cells have reverse pH levels of pHi > 7.4 and pHe ~6.7-7.1. Lowered extracellular pH is an important signature strongly associated with cancer invasion, progression, and metastasis. However, its malignant effects were mainly identified using cell and tissue studies [99, 100]. Thus, monitoring pH levels in living organs is critical for providing information on the physiological and pathological processes [101-104].

pH-activatable probes are mostly designed based on the cyanine (probe 25), BODIPY (probe 26), coumarin (probe 27), naphthalimide (probe 28), and rhodamine skeletons (probe 29) [105-109]. BODIPY derivatives can be used as common pH-activatable probes due to their excellent emission and photostability. By introducing various groups at corresponding sites, the fluorescent dyes can gain new emissions and realize pH sensing. Cyanine- and hemicyanine-based probes can realize pH sensing by the protonation and deprotonation of the pH sensing site. Rhodamine serves as a natural pH sensor for developing a variety of probes due to the acid-controlled spiro structure. Generally, other fluorescent groups like cyanine, BODIPY and coumarin participate in the energy transfer process of rhodamine probes, thus modulating the emission to realize the pH sensing.

---

**Figure 7. Activatable NIR-II probes for H2S.** (A) The fabrication and activation process of probe NIR-II@Si for H2S, based on trapping ZX-NIR and aza-BOD into the hydrophobic interior of self-assembled micellar aggregates. (B) NIR-II emission spectra of NIR-II@Si (10 µM ZX-NIR) in the presence of 100 µM NaHS over time, λex = 780 nm. Insets show photographs of the NIR-II@Si before and after the addition of NaHS. (C) Real-time images of cancers after subcutaneously injecting the NIR-II@Si (20 nmol ZX-NIR) into the tumor regions of HCT116 tumor-bearing mice. (D) The fabrication and activation process of Nano-PT, which is based on the self-assembly of an H2S-responsive small molecule capable of excellent photothermal conversion efficiency. (E) Time-dependent NIR-II emission spectra of Nano-PT (20 µM SSS) treated with 100 µM NaHS, λex = 790 nm. Inset shows photographs of the H2S-activated NIR-II emission. (F) Ratio of tumor weight of HCT116 tumor-bearing mice in different groups relative to that in untreated mice and photographs of tumor tissues. (G) The structure of WH, based on BODIPY skeleton and 4-Nitrothiophenol for specific recognition site. (H) NIR-II fluorescence spectra of WH-3 in the presence of NaHS (1-110 µM). Inset shows photographs of the NIR-II emission activated by varying NaHS. (I) Relative fluorescence intensity of different-sized tumor mice treated with the WH-3. Figures adapted with permission from [86, 93, 94]. Copyright © 2018, John Wiley and Sons. Copyright © 2018, and Copyright © 2021, American Chemical Society.
Gastric acid is a key factor in maintaining normal upper gastrointestinal function and can be used as a valuable biomarker. In 2019, a series of benzothiopyrylium pentamethine cyanines BTCs were reported by introducing electron-donating diethylamino moieties to overcome the solvatochromism-caused quenching and achieve stable NIR-II emission. The selected BTC1070 with the longest wavelength shows pH-responsive properties in an aqueous solution. When the pH values changed from 5 to 0 (Figure 9B), the blue-shifted fluorescence and enhanced intensity were observed under 808 nm excitation. The excellent responsive pH range is optimized to 1-4 from the sigmoidal equation plot of fluorescence ratio at the wavelength of 1000-1300 nm and 900-1300 nm (Figure 9C). The protonation mechanism is proved to be protonation on nitrogen atoms, resulting in ratiometric fluorescence response to various pH through the inhibition of ICT effect (Figure 9A). Based on the above property, ratiometric imaging in vivo was conducted for quantification of gastric pH, showing good agreement with measurement by standard pH meter. Noninvasive NIR-II imaging at ~2-4 mm tissue depth in the BTC1070-injected mice shows a clear stomach profile and significant difference in pseudo-color at two pH environments (Figure 9D-F) [110]. This work provides a strategy for pH-activatable probes based on the modulation of the π-electron system of benzothiopyrylium or other heterocycles. Developing brighter probes with longer emission wavelength is the challenge for further application.
In 2020, a new class of polymethine dyes NIRII-RTs were designed to serve as effective NIR-II platforms for the development of activatable bioimaging probes by introducing the carboxylic acid functional group. NIRII-RT-pH shows increasing fluorescence intensity at 925/1000 nm with the pH regulated from 4.0 to 2.2 (Figure 9G-H). A series of target-activatable NIRII-RT probes are successfully applied to the NIR-II imaging, confirming the feasibility of this novel design stratagem [111]. This work unlocks the potential of cyanine fluorophores and provides bright design ideas for target-activatable probes.

A series of pH transition-point adjustable sensors (pTAS) are developed by regulating the component ratio of NIR-II emission aza-BODIPY donor (NAB) and pH activatable rhodamine-based acceptor (NRh) in FRET system (Figure 10A). With pH changing from 8.30 to 4.88, the fluorescence intensity of pTAS at 940 nm declined obviously, while the fluorescence emission at 1026 nm was observed (Figure 10B). Thereinto, pTAS-1~3, the fluorescence intensity ratio of Peak 1 (940 nm) and Peak 2 (1026 nm) at pH 8.30-4.88 show satisfied pH response ability with well-fitted sigmoidal Boltzmann functions. pTAS-1~3 have the corresponding pH response regions 6.11-6.88 (ΔpH=0.77), 6.43-7.09 (ΔpH=0.66), and 6.63-7.22 (ΔpH=0.59), respectively. More importantly, the combination of three pH response regions provides a twofold widened pH detection range of 6.11-7.22, which is regulated by the NAB-NRh molar ratio. pTAS-2 and pTAS-3 are successfully applied to tumor pH monitoring, illustrating invasive vascular occlusion-induced lactic acid accumulation at the tumor site and the buffering ability of fluid in the tumor (Figure 10C-F) [100]. This work provided a novel FRET design strategy for pH-activatable probes with a widened pH detection region of 6.11-7.22 and may accelerate its clinical application.
Figure 10. Activatable NIR-II probes for pH. (A) The structure and detection mechanism of pTAS. (B) Fluorescence intensity ratio ($F_{940\text{nm}} / F_{1026\text{nm}}$) of four pTAS as a function of pH. The ratiometric fluorescence images of tumors during the two pH changing processes after administration of pTAS-2 (C) and pTAS-3 (E), respectively. (D) and (F): Corresponding comparison of the pH changing in two processes by ratiometric fluorescence imaging and microelectrode pH meter. Figures adapted with permission from[100]. Copyright © 2021, John Wiley and Sons.

Hypoxia-activatable probes

Hypoxia is a feature of most tumors and exhibits chemo- or radiation resistance unfavorable for cancer therapies [112-114]. Hypoxia causes the overexpression of nitroreductase (NTR), thus the quantitative detection of NTR can be used to evaluate the tumor hypoxic degree. The hypoxia-activatable single-molecule probe IR1048-MZ was designed by conjugating an electron-with drawing group (2-(2-nitroimidazolyl) ethylamine, MZ) with a NIR-II dye IR-1048 (Figure 11A) [115]. The MZ group of IR1048-MZ was reduced to the corresponding amine group in the presence of NTR, leading to the inhibition of electron transfer and the emerging NIR-II fluorescence and PA signal of IR1048-MZ (Figure 11B). The fluorescence intensity at the peak wavelength of 1046 nm excited by 980 nm increased linearly with the increasing NTR concentration (0-10 μg/mL) (Figure 11C). Furthermore, the detection limit value of NTR was found to be 43 ng/mL. The NIR-II fluorescence imaging in vivo was conducted in bearing subcutaneous A549 tumor mice to observe the response to tumor hypoxia. IR1048-MZ showed the highest NIR-II fluorescence signal at 14 h, meanwhile, no obvious background signal was observed in the process (Figure 11D). Moreover, the hypoxia-activated photothermal therapy of IR1048-MZ showed outstanding phototherapy efficacy with rapid temperature increases. Improving the biocompatibility of IR1048-MZ can facilitate the further clinical application.
Viscosity-activatable probes

Viscosity is a key indicator of biological microenvironments related to various physiological and pathological processes. Monitoring the levels of viscosity can provide critical information for related diseases [116, 117]. The developed viscosity-activatable probes show various strategies, including interactions between the targeting group and the skeleton (probe 30), conjugation effect of D-n-A structure (probe 31), fluorescent molecular rotors based on fluorescence lifetime imaging (probe 32) etc. [118-120]. The targeting groups are usually the lysosomal and mitochondria localization group like morpholine, pyridinium cations, and the skeletons are usually the Cy, BODIPY, coumarin, and rhodamine. The ICT, FRET and PET effects of these probes are controlled by viscosity, thus regulating fluorescence intensity for sensing.

A series of viscosity-activatable NIR-II emissive probes WD-X were designed and synthesized for tracing the variation of viscosity in diabetes-induced liver injury in vivo, screening the most optimized WD-NO2. The probes are designed by connecting the BODIPY dye modified with different groups and 1-ethyl-2-methyl-benz[c,d] iodolium salt with vinyl bond. The vinyl bond, as well as the C-N single bond of the BODIPY moiety of WD-X, can’t rotate freely at high viscosities, resulting in strong fluorescence intensity due to the favorable conjugate structure (Figure 12A). With the increase of viscosity (the glycerol content increasing from 0 to 95%), WD-NO2 showed a 31-fold fluorescence intensity enhancement at 982 nm. Meanwhile, the relationship between the fluorescence intensity of WD-NO2 and viscosity (1.52-925 cP) is consistent with the Forster-Hoffmann linear equation: log I = 0.4886 log η + 1.8604 (R^2 = 0.9916) (Figure 12B-C). This quantitative relationship...
endows visualization of the variation of viscosity in diabetes-induced liver injury \textit{in vivo}. The fluorescence intensity was enhanced in mice treated with monensin (Mon), nystatin (Nys), and lipopolysaccharide (LPS), respectively, compared with the control group injected with probe only (Figure 12D-E) \cite{121}. This work firstly reported a NIR-II emissive viscosity-activatable fluorescent probe through a novel structure design, which gives more ideas for the development of viscosity-activatable molecular probes in the NIR-II region. Improving the biocompatibility and extending the NIR-II emission to a longer wavelength are the challenges for further application.

**Enzyme-activatable probes**

The abnormal expression of enzymes is a promising biomarker of tumors, and enzyme-activatable probes were developed harnessing the merits of enzymes such as high catalytic efficiency and specific substrate selectivity \cite{122-124} (Table 1 and Figure 13-15). Based on the high activity and specificity of the enzyme, the strategy of enzyme-activatable probes is based on the reaction of the substrates and the enzyme. The activatable probes for nitroreductase (NTR), quinone oxidoreductase isozyme 1 (NQO1), alkaline phosphatase (ALP), \(\gamma\)-Glutamyltransferase (L-GGT), etc. have been developed, and each type of probe has its corresponding recognition site. The structures of NTR, ALP, NQO1, \(\gamma\)-GGT-activatable probes are designed upon corresponding substrates of p-nitrobenzyl moiety (probe 33), phosphate group (probe 34), quinone moiety (probe 35), \(\gamma\)-glutamyl group, conjugated (probe 36) with fluorophores, respectively \cite{125-128}.

![Figure 12. Activatable NIR-II probes for viscosity.](https://www.thno.org)
The diverse enzyme-activated fluorescent probes were reported, which are designed by combining BODIPY platforms with enzymic substrates using a self-immolative benzyl thioether linker. These NIR probes are nitroreductase (NTR), quinone oxidoreductase isozyme 1 (NQO1), or alkaline phosphatase (ALP) probes by different modifications (Figure 13A), exhibiting specific enzyme detection (Figure 13B). The fluorescence intensity of NTR-InD is 12-fold increased under the treatment of NTR (Figure 13C). The NIR-II imaging of A549 subcutaneous xenograft nude mice injected with NTR-InD shows a high tumor-to-normal tissue ratio from the tumor-derived enzyme (Figure 13D-E) [129]. Furthermore, the NIR-II signal detected by NTR-InD has deeper detection and higher T/N than the NIR-I signal by NTR-ImI, showing the potential in vivo tumor imaging of NIR-II activatable probes. The coupling of BODIPY platforms with different enzymic substrates in this work provides a novel design strategy for enzyme-activatable fluorescence probes. However, optimization of the water solubility by using the supramolecular assembly or hydrophilic groups is the challenge for further work.

In 2021, an NTR-activatable NIR-II fluorescence probe RHC-NO₂ was developed based on the rhodamine hybrid polymethine framework and a nitro group as recognition moiety and was
successfully applied in fluorescence imaging of tumors (Figure 14A). After the reaction of RHC-NO$_2$ with NTR, 14-fold enhanced fluorescence was produced at 921 nm. RHC-NO$_2$ showed a good linear relationship with the concentration of NTR, which can be applied to detect the concentration of NTR in the NIR-II window (Figure 14B-C). RHC-NO$_2$ was successfully applied in the fluorescence imaging of two kinds of murine tumor models (A549 and HeLa tumors), and tumor margins were clearly observed (Figure 14D-E) [130]. This work provides a convenient way to delineate the tumor margins for related diagnosis and treatment research. However, the low QY limits further clinical application, and further research may focus on the long emission wavelength and high QY.

N-acetyl-β-d-glucosaminidase (NAG) received considerable attention due to its clinical implications as a sensitive and specific biomarker for renal diseases [131, 132]. In 2021, A NAG-activatable probe BOD-II-NAG is developed by incorporating N-acetyl-β-d-glucosamine residues into BODIPY-based NIR fluorescent probes via a self-elimination linker (Figure 15A). In the presence of NAG, BOD-II-NAG turns on NIR-II fluorescence response at 1000 nm due to the hydrolyzation of N-acetyl-β-d-glucosamine residues from probes catalyzed by NAG. BOD-II-NAG displayed increasing fluorescence intensity treated with increasing NAG concentrations, which shows a perfect linear relationship (Figure 15B-C). In vivo NIR-II imaging was conducted on acute kidney injury (AKI) and chronic kidney mice (CKD) for tracking NAG activity. In the cisplatin-induced AKI imaging, BOD-II-NAG showed obvious NIR-II signals in the early stage of the AKI due to the reduced autofluorescence, high sensitivity, and rapid response (Figure 15D-F). In the diabetic nephropathy CKD imaging, BOD-II-NAG showed more obvious and clearer NIR-II signals in the CKD group than the control group (Figure 15G-H) [133]. The imaging results indicated that BOD-II-NAG has the potential to diagnose AKI or CKD. This work shows the huge advantage of activatable NIR-II probe BOD-II-NAG compared with the NIR-I probe BOD-I-NAG. Improving the biocompatibility of the probe may be helpful for the earlier diagnosis of related diseases in vivo.

Figure 14. Activatable NIR-II probes for NTR. (A) The structure and mechanism of RHC-NO$_2$ for NTR. (B) The fluorescence spectra of RHC-NO$_2$ with and without NTR. (C) The linear fitting plot of ΔF against the concentration of NTR. (D) NIR-II images of A549 tumor-bearing mice after injection of RHC-NO$_2$. (E) Quantified fluorescence intensity of dissected organs and the tumor. Figures adapted with permission from [130]. Copyright © 2021, Royal Society of Chemistry.
Dually-activatable probes

Responsive probes associated with a single molecule are easy to emit “false positive” signals, while probes activated by two or more pathological changes make the imaging precise and become more attractive (Table 1 and Figure 16-18) [102, 134-141]. An activatable NIR-II nanoprobe HISSNPs was developed, which responds to dual-pathological-parameter to control the fluorescence condition for tumor imaging. Meanwhile, the “dual-lock-and-key” probe with more accurate results is designed for the first time. The HISSNPs was constructed by following steps. Firstly IR-1061, hydrophobic cyanine dyes, and HA-hydrophilic hyaluronic acid were used to form the amphipathic HA polymers, further assembled into “single lock-and-key” nanoparticles HINPs. Furthermore, the “dual-lock-and-key” activatable HISSNPs was designed by crosslink of added disulfide with the HA of HINPs. The HISSNPs turn on its NIR-II fluorescence in the presence of hyaluronidase and thiols (Figure 16A). The DLS shows particle size of HISSNPs changed from monodispersity to polydisperse in the presence of Hyal and GSH, while no obvious changes under the single stimulus (Figure 16B). The HISSNPs shows the extremely enhanced signal in the presence of Hyal and GSH (Figure 16C), combing with the DLS results to confirm the correlation between the fluorescence intensity and the aggregation degree of IR-1061. The “dual lock-and-key” probe HISSNPs exhibits about fivefold higher greater tumor-to-normal tissue ratio than “single-lock-and-key” nanoparticles HINPs, achieving a better resolution between tumor region and normal tissues (Figure 16D-E) [142]. However, improving the water solubility and biocompatibility of HISSNPs is the challenge for further work.
A dually responsive probe BOD-NH-SC was reported, which applies an N-Methyl-2-methoxy-aniline moiety for NO-responsive site and 4-nitrobenzenethiol-substituted BODIPY for H2S-responsive site (Figure 17A). BOD-NH-SC emits bright NIR-II fluorescence after being treated with successive NO and H2S, resulting in the formation of BOD-NO-SH. BOD-NO-SH shows cycled S-nitrosation in the presence of NO and subsequent transnitrosation processes initiated by H2S, which is in the form of repeated colors changing from NIR-II fluorescence at 936 nm to NIR fluorescence at 645 nm (Figure 17B-C). Both colonic smooth muscle and HepG2 cells treated with BOD-NH-SC show bright fluorescence signals in the red channel (650-660 nm) with minimal fluorescence in the NIR-II channel (900-1000 nm) in the NO-pretreated process, while increasing fluorescence signals in the NIR-II channel with diminishing signal in the red channel in the presence of NaHS for H2S-initiated reaction (Figure 17D-E) [143]. The results confirm the visualization of the dynamic condition of NO and H2S in living cells with a single fluorescent probe for the first time. Meanwhile, extending the emission to a longer wavelength can boost the clinical translation.

Acid-base balance maintains basic life activities, especially for normal urology and digestion [101, 144, 145]. In 2021, a ROS/RNS and base dual activatable NIR-II molecular probe PN910 was developed based on modulating the ICT effect of a merocyanine fluorescent probe (Figure 18A). PN910 shows an increasing fluorescence intensity with the increase of H2O2 and ONOO− at pH 8.0, while weak fluorescence in a neutral environment (Figure 18B-E). This is favorable for the imaging of alkaline microenvironments, such as the urine and the colon. Thus, LPS-induced cystitis and DSS-induced colitis were studied by in vivo imaging of PN910. In colitis imaging, the fluorescence signal of acute colitis mice was 10-fold higher than the control group mice (Figure 18F, I). In cystitis imaging, a brilliant fluorescence signal was observed in the pH 8.0 environment compared with neglected fluorescence in the control groups (pH 7.4 with LPS injection, pH 8.0 without LPS injection) were nearly non-fluorescent (Figure 18G-H) [146]. Imaging results confirmed that PN910 was a reliable probe for the monitoring of colitis and cystitis through in vivo imaging.

Conclusions and perspective

Activatable NIR-II fluorescence probes hold great promise in detecting disease-related biomarkers with high resolution and fast response [32, 147-149], and show potential in clinical translation. Besides, several aspects ought to be taken into account when design the responsive NIR-II fluorescence probes to boost the development and clinical translation.

First, biocompatibility is critical for clinical approval, thus the stability and metabolic property should be considered when designing the probes [150]. Especially, for the nanostructures, controlling the hydrodynamic sizes below 5.5 nm can drive them excreted via the urinary system to decrease cumulative toxicity and benefit their potential clinical applications [151-153]. In addition, the water solubility of organic fluorescent probes is important for their metabolism, thus hydrotropic groups can be introduced to modify the fluorescent probe skeleton.
Second, the photoluminescence properties, especially high QY, should be reckoned [154-163]. Based on the photochemical mechanisms such as PET [164-167], FRET [168-170], ICT [171-173], fluorescent probes with long emission wavelengths will be developed continuously. Additionally, the QY and photochemical stability are critical for the usefulness of the fluorescent probes. To date, a structure-function relationship that can guide the design to improve the QY has not been established, while structural modification of aromatic systems that possess high QY tends to be a useful strategy to design activatable organic fluorescent probes. The photodegradation of organic fluorescence probes can follow different oxygen-dependent or oxygen-independent mechanisms, and involve such parameters as fluorophore structure, medium conditions, irradiation power. The main strategy for enhancing the photostability is to improve the design of fluorophores, particularly to attach protective and anti-fading groups to the molecular nuclear. For instance, shielding units were designed to protect the D-A-D structure and can improve the photochemical stability of the organic probes [174, 175]. With high QY and photochemical stability, the activatable fluorescence probes are promising for bioimaging.

Third, improving targeting is another aspect to be considered for developing activatable NIR-II fluorescence probes, and several strategies such as binding with targeting molecules, introducing extracorporeal stimulus, and designing dual or multiple responsive reactivities may motivate the development [21, 176-180]. In addition, probes based on fluorescence lifetime imaging provide novel strategies for the development of activatable probes [181].

Figure 17. Activatable NIR-II probes for NO and H₂S. (A) The structure of BOD-NH-SC and the response process on NO and H₂S. (B) Time-dependent fluorescence spectra of BOD-NH-SC (5 µM) in the presence of H₂S (100 µM). (C) Fluorescence spectra varying with cycled S-nitrosation and transnitrosation processes. Imaging in NIR-II fluorescence channel of (D) HepG2 and (E) colonic smooth muscle cells in the alternating presence of NO and H₂S. Figures adapted with permission from [143]. Copyright © 2021. John Wiley and Sons.
Fourth, the theranostic design of activatable NIR-II fluorescent probes is an important approach for diseases treatment. For instance, besides the photon down conversion and photothermal conversion, exploring novel energy conversion modes could provide new ideas for tumor theranostics in the NIR-II region. Converting the energy into oxidation stress through the low-energy NIR-II photon excitation is a strategy for therapeutic purposes [150].

In conclusion, a long-term effort is still needed to address the challenges and the NIR-II fluorescence probes exhibit promising prospects for rapid development and clinical translation.

Acknowledgements

This work was financially supported by the National Key Research and Development Program of China (2021YFF1200030), the National Natural Science Foundation of China (Grant Nos. 91859101, 81971744, U1932107, 82001952, and 11804248), Outstanding Youth Funds of Tianjin (2021JQ-0009), National Natural Science Foundation of Tianjin (Nos. 19JCZDJC34000 and 20JCYBJC00940), the Innovation Foundation of Tianjin University, and CAS Interdisciplinary Innovation Team (JCTD-2020-08).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Liu P, Mu X, Zhang X, Ming D. The near-infrared-II fluorophores and advanced microscopy technologies development and application in bioimaging. Bioconjug Chem. 2020; 31: 260-275.
2. Yang Q, Ma H, Liang Y, Dai H. Rational design of brightness NIR-II organic dyes with S-D-A-D-S structure. Acc Mater Res. 2021; 2: 170-83.
3. Wang F, Ren F, Ma Z, Qu L, Gourgues R, Xu C, et al. Non-invasive confocal fluorescence imaging of mice beyond 1700 nm using superconducting nanowire single-photon detectors. bioRxiv. 2021; doi: 10.1101/2021.08.13.456312.
4. Dai H, Ma Z, Wang F, Zhong Y, Salazar F, Li J, et al. Advancing nanomedicine with cross-link functionalized nanoparticles for rapid excretion. Angew Chem Int Ed Engl. 2020; 59: 1109-12.
5. Zhu S, Tian R, Antaris AL, Chen X, Dai H. Near-infrared-II molecular dyes for cancer imaging and surgery. Adv Mater. 2019; 31: 1900321.
6. Wang H, Mu X, Yang J, Liang Y, Zhang X, Ming D. Brain imaging with near-infrared fluorophores. Coord Chem Rev. 2019; 380: 350-71.
7. Antaris AL, Chen H, Diao S, Ma Z, Zhang Z, Zhu S, et al. A high quantum yield molecule-protein complex fluorophore for near-infrared II imaging. Nat Commun. 2017; 8: 15269.
8. Huang H, Sun Z, Yang H, Yang X, Wu F, Sun Y, et al. Precise examination of peripheral vascular disease for diabetics with a novel multiplexed NIR-II fluorescence imaging technology. Nano Today. 2022; 43: 101178.

9. Liu H, Heng F, Chen Z, Jiang C, Guo M, et al. Atomic-precision gold NPs for NIR-II imaging. Adv Mater. 2019; 31: 1901015.

10. Ma H, Wang J, Zhang X. Near-infrared II emissive metal clusters: from atom physics to biomedicine. Coord. Chem. Rev. 2021; 448: 214184.

11. Ding S, Lu L, Zhang Q. Recent progress in NIR-II emitting lanthanide-based nanoparticles and their biological applications. J Rare Earths. 2020; 38: 451-63.

12. Pei P, Hu H, Chen Y, Wang S, Chen J, Ming J, et al. NIR-II ratiometric lanthanide-dye-hybrid nanoprobes doped bioscaffolds for in situ bone repair monitoring. Nano Lett. 2022.

13. Zhao M, Li B, Zhang H, Zhang F. Activatable fluorescence sensors for in vivo bio-detection in the second near-infrared window. Chem Sci. 2021; 12: 3448-59.

14. Zhang F, Zhu X, Liu X, Zhao M, Pei P, Chen J, et al. High-fidelity NIR-II multimodal lifetime bioimaging with bright double interface lanthanide nanoparticles. Angew Chem Int Ed. 2021; 60: 23345-51.

15. Zhang F, Zhang H, Fan Y, Pei P, Sun C, Lu L. Tuned sensitized 1280 nm excitation and 1525 nm emission NIR-II fluoronanocrystals for in vivo imaging information storage and decoding. Angew Chem Int Ed. 2019; 58: 10153-7.

16. Zhang F, Yao C, Chen Y, Zhao M, Wang S, Wu B, et al. A bright, real-time NIR-II brush macromolecular probe with long blood circulation time for kidney disease bioimaging. Angew Chem Int Ed. 2022; 61: e20211427.

17. Zhang F, Chen Y, Pei P, Lei Z, Zhang X, Yin D. A promising NIR-II fluorescence sensor for peptide-mediated long-term monitoring of kidney dysfunction. Angew Chem Int Ed. 2021; 60: 15809-15.

18. Wang T, Wang S, Liu Z, He H, Zhang Y, Zhao M, et al. Bright quantum dots 1,600 nm in the NIR-IIb window for deep tissue fluorescence imaging. Proc Natl Acad Sci U S A. 2018; 115: 6590-5.

19. Sun C, Zhan Y, Cui R, Ma Z, Wan H, Wang F, et al. Bright quantum dots for NIR-II imaging: multiplexed lifetime bioimaging with bright double interfaced lanthanide nanoparticles. Angew Chem Int Ed. 2021; 60: 15809-15.

20. Sun C, Zhan Y, Cui R, Ma Z, Wan H, Wang F, et al. Bright quantum dots for NIR-II imaging: multiplexed lifetime bioimaging with bright double interfaced lanthanide nanoparticles. Angew Chem Int Ed. 2021; 60: 23345-51.

21. Zhang F, Zhang H, Fan Y, Pei P, Sun C, Lu L. Tuned sensitized 1280 nm excitation and 1525 nm emission NIR-II fluoronanocrystals for in vivo imaging information storage and decoding. Angew Chem Int Ed. 2019; 58: 10153-7.

22. Zhang F, Yao C, Chen Y, Zhao M, Wang S, Wu B, et al. A bright, real-time NIR-II brush macromolecular probe with long blood circulation time for kidney disease bioimaging. Angew Chem Int Ed. 2022; 61: e20211427.

23. Zhang F, Chen Y, Pei P, Lei Z, Zhang X, Yin D. A promising NIR-II fluorescence sensor for peptide-mediated long-term monitoring of kidney dysfunction. Angew Chem Int Ed. 2021; 60: 15809-15.

24. Wang T, Wang S, Liu Z, He H, Zhang Y, Zhao M, et al. Bright quantum dots 1,600 nm in the NIR-IIb window for deep tissue fluorescence imaging. Proc Natl Acad Sci U S A. 2018; 115: 6590-5.

25. Yi H, Ghosh D, Ham M-H, Qi J, Barone PW, Strano MS, et al. M13 phage-functionalized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescence imaging of targeted tumors. Nano Lett. 2012; 12: 1176-83.

26. Yi H, Ghosh D, Ham M-H, Qi J, Barone PW, Strano MS, et al. M13 phage-functionalized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescence imaging of targeted tumors. Nano Lett. 2012; 12: 1176-83.

27. Zebibula A, Alifu N, Xia L, Sun C, Yu X, Xue D, et al. Ultrastable and dynamic vascular imaging. Nat Commun. 2019; 10: 5043.

28. Liu T, Xiao B, Xiang F, Tan J, Chen Z, Zhang X, et al. Ultrasound copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases. Nat Commun. 2020; 11: 2788.

29. Hou J, Yu K, Sunwoo K, Kim WY, Koo S, Wang J, et al. Fluorescent imaging of reactive oxygen species in m etabolic and inflammatory signaling. Circ Res. 2019; 124: 877-902.

30. Li B, Lu L, Zhao M, Lei Z, Yin D. An efficient 1064 nm NIR-II excitation fluorescent molecule dye for deep-tissue high-resolution dynamic bioimaging. Angew Chem Int Ed. 2018; 57: 7483-87.

31. Zhu S, Hu Z, Tian R, Yung BC, Yang Q, Zhao S, et al. Repurposing cyanine NIR-I dyes accelerates clinical translation of near-infrared-II (NIR-II) bioimaging. Adv Mater. 2020; 32: 2070086.

32. Wang Q, Li C, Li W, Li Z, Chen G, Liu H. An activatable NIR-II nanoprobe for in vivo early real-time diagnosis of traumatic brain injury. Angew Chem Int Ed. 2019; 58: 24-57.

33. Wang J, Lu Q, Cai J, Wang Y, Lai X, Qiu Y, et al. Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop. Nat Commun. 2019; 10: 5043.

34. Hou J, Yu K, Sunwoo K, Kim WY, Koo S, Wang J, et al. Fluorescent imaging of reactive oxygen species in m etabolic and inflammatory signaling. Circ Res. 2018; 122: 877-902.

35. Li B, Zhao M, Feng L, Dou C, Ding S, Zhou G, et al. Organic NIR-II molecule with long blood half-life for in vivo dynamic vascular imaging. Nat Commun. 2020; 11: 3102.

36. Mu J, Xiao M, Shi Y, Geng X, Li H, Yin Y, et al. The chemistry of organic contrast agents in the NIR-II window. Angew Chem Int Ed. 2021.

37. Cui J, Wang C, Fu Q, Song J, Zou J, Li L, et al. A generic self-assembly approach towards phototheranostics for NIR-II fluorescence imaging and Luminotherapy. Acta Biomater. 2020; 104: 152-6.

38. Zhu R, Su L, Dai J, Li Z, Bai S, Li Q, et al. Biologically responsive plasmonic assemblies for second Near-Infrared window photoacoustic imaging-guided concurrent chem-phototherapy. ACS Nano. 2020; 14: 3991-4006.

39. Tian Y, Ma H, Lai J, Ma H, Li L, et al. In vivo imaging multiplexed NIR-II probes for lymph node-invaded cancer detection and imaging-guided surgery. Adv Mater. 2020; 32: 2070086.

40. Liu H, Liu Z, Zhu H, Zhao M, Tei Z, Zhang F. A promising NIR-II fluorescence sensor for peptide-mediated long-term monitoring of kidney dysfunction. Angew Chem Int Ed. 2021; 60: 15809-15.
85. Tang Y, Li Y, Wang Z, Pei F, Hu X, Ji Y, et al. Organic semiconducting
77.
68. Wang J-Y, Liu Z-R, Ren M, Kong X, Liu K, Deng B, et al. A fast-responsive turn
71. Zhang R, Zhao J, Han G, Liu Z, Liu C, Zhang C, et al. Real-time discrimination
69. Li R-Q, Mao Z-Q, Rong L, Wu N, Lei Q, Zhu J-Y, et al. A two-photon
66. Zhang Z, Fan J, Cheng G, Ghazali S, Du J, Peng X. Fluorescence completely
87. Deng Z, Bi S, Jiang M, Zeng S. Endogenous H\textsubscript{2}S-activated orthogonal second
65. Mulay SV, Choi M, Jang YJ, Kim Y, Jon S, Churchill DG. Enhanced fluorescence turn-on imaging of hydroxylic acid in living immune and cancer cells. Chem Eur J. 2016; 22: 9642-8.
63. Zhang Z, Fan J, Cheng G, Ghazali S, Du J, Peng X. Fluorescence completely
115. Meng X, Zhang J, Sun Z, Zhou L, Deng G, Li S, et al. Hypoxia- triggered single
106. Li J, Li X, Jia J, Chen X, Lv Y, Guo Y, et al. A ratiometric near-infrared
105. Lee MH, Park N, Yi C, Han JH, Hong JH, Kim KP, et al. Mitochondria-
90. Velusamy N, Binoy A, Bobba KN, Nedungadi D, Mishra N, Bhunia S. A bioorthogonal fluorescence probe for mitochondrial hydrogen sulfide: new strategy for cancer cell labeling. Chem Commun. 2017; 53: 8802-5.
91. Cao M, Chen H, Chen D, Li J, Liu S, Chen M, et al. Naphthalimide-based fluorescent probe for selectively and specifically detecting glutathione in the lysosomes of living cells. Chem Commun. 2016; 52: 721-4.
92. Liu Z, Zhou X, Miao Y, Hu Y, Kwon N, Wu X, et al. A reversible fluorescent probe for real-time quantification of cellular glutathione. Angew Chem Int Ed Engl. 2017; 56: 5812-6.
93. Shi B, Yan Q, Tang J, Xin K, Zhang J, Zhu Y, et al. Hydrogen sulfide-activatable second near-infrared fluorescent nanoassemblies for targeted photothermal cancer therapy. Nano Lett. 2018; 18: 6411-6.
94. Dou K, Feng W, Fan C, Cao Y, Xiang Y, Liu Z. Flexible designing strategy to construct activatable NIR-II fluorescence probes with emission maxima beyond 1200 nm. Anal Chem. 2021; 93: 4006-14.
95. Pan Y, Lei S, Zhang J, Qu J, Huang P, Lin J. Activatable NIR-II fluorescence probe for highly sensitive and selective visualization of glutathione in vitro. Anal Chem. 2021; 93: 17103-9.
96. Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019; 18: 10.
97. Xiao Y, Zhang T, Ma X, Yang QC, Yang LL, Yang SC, et al. Microenvironment-responsive prodrug-induced pyroptosis boosts cancer immunotherapy. Adv Sci. 2022; 9: e2101840.
98. Tae J, Yang G, Zhou W, Qiu C, Chen L, Luo W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021; 14: 14.
99. More KN, Mun S-K, Kang J, Kim J-Y, Yee S-T, Chang D-J. Molecular design of fluorescence pH sensors based on reduced rhodol structure-pKa relationship and its application to pH sensing. Anal Chem. 2021; 94: 184-197.
100. Zhao M, Wang J, Lei Z, Lu L, Wang S, Zhang H, et al. NIR-II pH sensor with a FRET adjustable transition point for in situ dynamic tumor microenvironment visualization. Angew Chem Int Ed Engl. 2021; 60: 5001-5.
101. Hashimoto R, Mitsumori M, Kikuta J, Yari S, Bull SD, Ishii M, et al. An acid-activatable fluorescence probe for imaging osteocytic bone resorption activity in deep bone cavities. Angew Chem Int Ed Engl. 2020; 59: 2096-100.
102. Voskuil F, Steinkamp P, Zhao T, van der Vegt B, Kolter M, Doff JJ, et al. Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-Activatable nanoprobe for fluorescence-guided surgery. Nat Commun. 2020; 11: 3257.
103. Mao Q, Lyu Y, Ding D, Pu K. Semicontrolling oligomer nanoparticles as an activatable photoacoustic contrast agent with amplified brightness for in vivo imaging of pH. Adv Mater. 2016; 28: 3662-8.
104. Han X, Shou K, Chen S, Qu C, Wang Z, Jiang L, et al. Smart self-assembly amphiphilic cyclopeptide-dye for near-infrared window-II imaging. Adv Mater. 2021; 33: 2006902.
105. Lee MH, Park N, Yi C, Han JH, Hong JH, Kim KP, et al. Mitochondria-immobilized pH-sensitive off-on fluorescence probe. J Am Chem Soc. 2014; 136: 14136-42.
106. Wang S, Fan Y, Li D, Sun C, Lei Z, Lu L, et al. A ratiometric near-infrared fluorescence strategy based on spiropyran in situ switching for tracking dynamic changes of live-cell lysosomal pH. Dyes Pigments. 2019; 166: 433-42.
107. Usano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, et al. Selective viable cancer cells with pH-activatable fluorescent probes. Nat Med. 2009; 15: 104-9.
108. Wycisk V, Achazi K, Hillmann P, Hirsch O, Kuehne C, Dernedde J, et al. Responsive contrast agents: synthesis and characterization of a tunable series of pH-sensitive fluorophores. ACS Chem Biol. 2019; 14: 808-17.
109. Zhu H, Fan J, Xu Q, Li H, Wang J, Gao P, et al. Imaging of lysosomal pH changes with a fluorescent sensor containing a novel lysosome-locating group. Chem Commun. 2012; 48: 11768-9.
110. Voskuil F, Steinkamp P, Zhao T, van der Vegt B, Kolter M, Doff JJ, et al. Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-Activatable nanoprobe for fluorescence-guided surgery. Nat Commun. 2020; 11: 3257.
111. Li J, Li X, Jia J, Chen X, Lv Y, Gao Y, et al. A ratiometric near-infrared fluorescence strategy based on spiropyran in situ switching for tracking dynamic changes of live-cell lysosomal pH. Dyes Pigments. 2019; 166: 433-42.
112. Usano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, et al. Selective viable cancer cells with pH-activatable fluorescent probes. Nat Med. 2009; 15: 104-9.
Meng X, Yang Y, Zhou L, Zhang L, Lv Y, Li S, et al. Dual-responsive molecular motor for ratiometric imaging of mitochondrial viscosity in cells. Sens Actuators B Chem. 2019; 298: 126831.

Wang L, Xiao Y, Tian W, Deng L. Activatable rotor for quantifying lysosomal volume in living cells. J Am Chem Soc. 2021; 143: 2903-6.

Dou K, Huang W, Xiang Y, Li S, Liu Z. Design of activatable NIR-II molecular probe for in vivo elucidation of disease-related viscosity variations. Anal Chem. 2020; 92: 4177-81.

Schwerer S, Pavlova NN, Cinino FV, King B, Cai X, Sizemore GM, et al. Fibroblast pyruvate carboxylase is required for collagen production in the tumour microenvironment. Nat Metab. 2021; 3: 1484-99.

Xu D, Shao F, Bian X, Meng Y, Liang T, Lu Z. The evolving landscape of noncanonical functions of metabolic enzymes in cancer and other pathologies. Nat Metab. 2021; 33: 53-50.

Mu J, Lin J, Huang P, Chen X. Development of endogenous enzyme-responsive nanomaterials for theranostics. Chem Soc Rev. 2018; 47: 5554-73.

Zhang P, Jiang X-F, Nie X, Huang Y, Zeng F, Xia X, et al. A two-photon fluorescent sensor revealing drug-induced liver injury via tracking γ-glutamyltranspeptidase (GGT) level in vivo. Biomater. 2016; 80: 46-56.

Fei Q, Zhou L, Wang F, Shi B, Li C, Wang R, et al. Rational construction of probes rendering ratiometric response to the cancer-specific enzyme NQO1. Chem Phys Chem. 2017; 18: 8464-51.

Zhang Q, Li S, Fu C, Xiao Y, Zhang P, Ding C. Near-infrared m-tropic fluorescent probe for ratiometric detection of acetaminophen in human blood plasma. J Photochem Photobiol B Biol. 2019; 192: 111548.

Zhang X, Li X, Shi W, Ma H. Sensitive imaging of tumors using a nitroreductase-activated fluorescence probe in the NIR-II window. Chem Commun. 2021; 57: 8147-57.

Ma J, Zhang H, Peng F, Yang X, Li Z-L, Sun L, et al. Carbon dots as fluorescence nanoprobe for the determination of N-acetyl-β-D-glucosaminidase activity in human serum. Anal Chem Acta. 2020; 1101: 129-34.

Lee Y, Han H, Lee Y, Kang ES, Cha BS, Lee B-W. Elevated N-acetyl-β-D-glucosaminidase activity, a urinary tumoral damage marker, is a significant predictor of cardiot artery atherosclerosis in type 1 diabetes, independent of albuminuria: A cross-sectional study. J Diabetes Complications. 2021; 35: 77-83.

Tan J, Yin K, Ouyang Z, Wang R, Pan H, Wang Z, et al. Real-time monitoring renal impairment due to drug-induced AKI and diabetes-caused CKD using an NAG-activatable NIR-II nanoprobe. Anal Chem. 2021; 93: 16185-68.

Wang M, Hu R, Fang J, Fan J, Du P, Xie D. Chemosensor for in vivo biodistribution and toxicity of gold nanoclusters. Biomater. 2012; 33: 4628-38.

Zhou T, Wu T, Zhu L, Li Y, Chen L, Qian J. Self-confocal NIR-II fluorescence microscopy for in vivo imaging. bioRxiv. 2021; doi: 10.1101/2021.02.07.474649.

Jiang S, Huang K, Qiu J, Lin J, Huang P. Cancer nanotheranostics in the second near-infrared window: NIR-II fluorescence imaging and image-guided tumor surgery. J Biomed Opt. 2018; 9: 3105-10.

Zhen Y, Yu C, Fang Y, Fan J, Fan SJ. In vivo renal clearance, biodistribution, toxicity of gold nanoclusters. Biomater. 2012; 33: 4628-38.

Zhang X, Jiang Z, Wang J, Yang J, Chen J, Shen X, et al. Highly catalytic metallosupramolecular probes for imaging and targeting of endogenous enzymes in living cells. J Mater Chem B. 2019; 7: 443-50.

Feng Z, Li Y, Chen S, Yu X, Ying Y, Zheng J, et al. Fluorescence visualization of deep-buried hollow organs. bioRxiv. 2022; doi: 10.1101/2022.01.07.474649.

Zhao J, Wu T, Zou L, Li Y, Chen L, Qian J. Self-confocal NIR-II fluorescence microscopy for in vivo imaging. bioRxiv. 2021; doi: 10.1101/2021.12.19.474602.

Ni H, Wang Y, Tang Y, Yu W, Li D, He M, et al. Quantum dots assisted and NIR-II emissive in vivo two-photon microscopy. Photonics Res. 2021; 10: 189-96.

Hua J, Yang Z, Fan X, Li H, Li X, Li S, et al. A small-molecule diketopyrrolopyrrole-based dye for in vivo NIR-II fluorescence bioimaging. J Med Chem. 2021; 57: 14420-9.

He M, Li D, Zheng Z, Zhang H, Wu T, Geng W, et al. Ultra-deep through-skull mouse brain imaging via the combination of skull optical clearing and three-photon microscopy. bioRxiv. 2021; doi: 10.1101/2021.12.20.474649.

Daly B, Ling J, de Silva AP. Current developments in fluorescent PET (photoinduced electron transfer) sensors and switches. Chem Soc Rev. 2015; 44: 4201-03.

Lee MH, Kim JS, Sesseler JL. Small-molecule ratiometric fluorescent sensor for cations, anions, and biomolecules. Chem Soc Rev. 2015; 44: 4181-95.

Marx V. Probes: FRET sensor design and optimization. Nat Methods. 2017: 14: 949-53.

Sun Y, Tang X, Li X, Kong X, Tian M, Wang Y, et al. PET-ESIPT-based fluorescent probes for revealing the fluctuation of porcine oxidase (ONOO−) in living cells, zebrafish and brain tissues. Sens Actuators B Chem. 2022; 353: 131121.

Wu L, Huang C, Emery BP, Sedgwick AC, Bull SD, He X-P, et al. Förster resonance energy transfer (FRET)-based small-molecule sensors and imaging agents. Chem Soc Rev. 2020; 49: 5110-39.

Jia X, Chen Q, Yang Y, Tang Y, Wang R, Yu Y, et al. FRET-based m-tropic specific fluorescence probe for ratiometric detection and imaging of endogenous peroxynitrite: dyad of Cy3 and Cy5. J Am Chem Soc. 2016; 138: 1078-81.

Yang X, Yang Z, Yu G, Nie Z, Wang R, Chen Z. Polypyridyl complexes: an emerging paradigm for cancer therapy. Adv Mater. 2021; 34: 2017434.

Jia X, Li Y, Feng X, She M, Yao W, Leng X, et al. An ICT-based fluorescence probe guided by theoretical calculation for selectively mapping endogenous GSH in living cells. Sci Adv. 2019; 5: 1-8.

Yang Q, Ma H, Liang Y, Dai H. Rational design of high brightness NIR-II organic dyes with S-D-A-D-structure. Acc Chem Res. 2021; 2: 170-83.

Yang Q, Ma Z, Wang H, Zhou Z, Shu Z, Zhong Y, et al. Rational design of molecular fluorophores for biological imaging in the NIR-II window. Adv Mater. 2017; 29: 1605497.
176. Liu X, Chen H, Wang Y, Si Y, Zhang H, Li X, et al. Near-infrared manipulation of multiple neuronal populations via trichromatic upconversion. Nat Commun. 2021; 12: 5662.

177. Chen L, Wang W, Tian J, Bu F, Zhao T, Liu M, et al. Imparting multifunctionality to covalent organic framework nanoparticles by the dual-ligand assistant encapsulation strategy. Nat Commun. 2021; 12: 4556.

178. Liu X, Chen ZH, Zhang H, Fan Y, Zhang F. Independent luminescent lifetime and intensity tuning of upconversion nanoparticles by gradient doping for multiplexed encoding. Angew Chem Int Ed Engl. 2020; 60:7041.

179. Lu L, Li B, Ding S, Fan Y, Wang S, Sun C, et al. NIR-II bioluminescence for in vivo high contrast imaging and in situ ATP-mediated metastases tracing. Nat Commun. 2020; 11:4192.

180. Li B, Zhao M, Feng L, Dou C, Ding S, Zhou G, et al. Organic NIR-II molecule with long blood half-life for in vivo dynamic vascular imaging. Nat Commun. 2020; 11:3102.

181. Li B, Lin J, Huang P, Chen X. Near-infrared probes for luminescence lifetime imaging. Nanotheranostics. 2022; 6: 91-102.